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Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic 
progenitor cells in which several genetic and epigenetic aberrations have been described. 
Despite progressive advances in our understanding of the molecular biology of this dis-
ease, the outcome for most patients is poor. It is, therefore, necessary to develop more 
effective treatment strategies. Genetic aberrations affecting kinases have been widely 
studied in AML; however, the role of phosphatases remains underexplored. Inactivation 
of the tumor-suppressor protein phosphatase 2A (PP2A) is frequent in AML patients, 
making it a promising target for therapy. There are several PP2A inactivating mechanisms 
reported in this disease. Deregulation or specific post-translational modifications of PP2A 
subunits have been identified as a cause of PP2A malfunction, which lead to deregulation 
of proliferation or apoptosis pathways, depending on the subunit affected. Likewise, over-
expression of either SET or cancerous inhibitor of protein phosphatase 2A, endogenous 
inhibitors of PP2A, is a recurrent event in AML that impairs PP2A activity, contributing 
to leukemogenesis progression. Interestingly, the anticancer activity of several PP2A-
activating drugs (PADs) depends on interaction/sequestration of SET. Preclinical studies 
show that pharmacological restoration of PP2A activity by PADs effectively antagonizes 
leukemogenesis, and that these drugs have synergistic cytotoxic effects with conven-
tional chemotherapy and kinase inhibitors, opening new possibilities for personalized 
treatment in AML patients, especially in cases with SET-dependent inactivation of PP2A. 
Here, we review the role of PP2A as a druggable tumor suppressor in AML.
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iNTRODUCTiON
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic progenitor 
cells, which predominantly affects elderly adults. It is characterized by a differentiation blockade 
of the myeloid hematopoietic progenitor cells accompanied by uncontrolled proliferation. As a 
consequence, immature cells accumulate in bone marrow and peripheral blood. With the exception 
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATM, ataxia-telangiectasia mutated; CIP2A, 
cancerous inhibitor of protein phosphatase 2A; CML, chronic myeloid leukemia; LCMT1, leucine carboxyl methyltransferase 1; 
NK, natural killer; OA, okadaic acid; PADs, PP2A activating drugs; PKR, interferon-inducible dsRNA-activated protein kinase; 
PP2A, protein phosphatase 2A; SETBP1, SET binding protein 1; SPHK2, sphingosine kinase 2.
FiGURe 1 | Signaling pathways involving PP2A in AML. Schematic representation of known PP2A complexes involving different B regulatory subunits in AML 
cells. Cell survival is regulated by PR55α/B55α – mediated dephosphorylation of AKT (15, 16). PR55α/B55α also supports expression of miR-142-3p and 
suppresses expression of miR-191-5p, relevant miRNAs in AML (17). DNA damage response is impaired by dephosphorylation of ATM by PP2A-PR55α/B55α, 
which translocate to the nucleus by PKR (18). Extracellular survival signals activate SRC that suppresses the B subunit; when SRC is suppressed, PR55α/B55α is 
expressed, resulting in dephosphorylation of PKCα and suppression of PR61α/B56α protein expression, with concomitant induction of MYC (19). Apoptosis is 
regulated by activation of PR61α/B56α by PKR leading to dephosphorylation of BCL2 (20). PR61β/B56β regulates PIM1 contributing to tumor formation (21). 
PP2A-B56γ function in G2 is crucial to sustain normal G0/G1 control and this G2 PP2A function involves modulation of endogenous RAS signaling (22). PR61ϵ/
B56ϵ, which is downregulated in AML, controls caspase-mediated apoptosis (23).
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of acute promyelocytic leukemia, therapy for AML is not tar-
geted, and the intensity of therapy is driven by the prognostic 
subgroup. Cytogenetic and molecular genetic aberrations have 
been postulated as the most powerful markers for survival and 
therapy response in AML, with patients classified into favorable, 
intermediate or poor prognosis (1, 2). Although major improve-
ments have been achieved in the overall survival of adult cases 
≤60 years, most of the patients are older than 60 years, and in this 
group only 5–15% are cured (3, 4). Furthermore, the outcome in 
older patients, who are unable to receive intensive chemotherapy 
without unacceptable side effects, remains dismal, with a median 
survival of only 5–10 months (5–7). Therefore, it is necessary to 
develop more effective treatment strategies for this disease.
The uncontrolled growth of transformed cells is caused by the 
deregulation of multiple cellular pathways that are involved in 
normal growth control (8). Reversible phosphorylation is one of 
the mechanisms that cells use to maintain normal homeostasis, 
and is involved in several processes, such as proliferation, apop-
tosis, and differentiation; hence, kinases and phosphatases act 
as important checkpoint regulators (9). Numerous studies have 
focused on studying the aberrant kinase behavior in AML; how-
ever, although phosphatases are also essential to maintain the cor-
rect homeostasis, their role in AML has not been fully considered. 
In this review, we will focus on the role of protein phosphatase 2A 
(PP2A), inactivation of which is a recurrent event in AML, as a 
druggable tumor suppressor.
PROTeiN PHOSPHATASe 2A
Protein phosphatase 2A, one of the main serine/threonine phos-
phatases in mammalian cells, is a tumor suppressor that regulates 
several essential functions and counteracts most of the kinase-
driven intracellular signaling pathways (8, 10, 11) (Figure  1). 
PP2A inactivation occurs in several solid and hematological 
tumors, leading to sustained activation of survival pathways or 
inhibition of apoptotic pathways (12, 13). Studies with the potent 
tumor promoter okadaic acid (OA), which inhibits the enzymatic 
activity of PP2A, have contributed to our understanding of phos-
phatase functions (14).
Protein phosphatase 2A exists in two different forms: as a 
dimer and in a trimeric form (24). The dimeric form is known 
as the core enzyme and consists of a structural A subunit and 
a catalytic C subunit. These subunits are coded by two differ-
ent genes, which may further generate two distinct isoforms: 
PP2A-A (PPP2R1A/Aα and PPP2R1B/Aβ) and PP2A-C 
(PPP2CA/Cα and PPP2CB/Cβ) (Table 1). The trimeric form is 
an active holoenzyme complex that consists of three subunits: 
the above-mentioned scaffold (PP2A-A) and catalytic (PP2A-C) 
subunits, and a regulatory B subunit (PP2A-B) (Figure  1; 
Table  1). In its heterotrimeric form, the structural subunit 
mediates the interaction between the catalytic subunit with a 
variety of regulatory PP2A-B subunits; whereas in the dimeric 
form, PP2A-A acts as a regulator by changing the catalytic 
TABLe 1 | PP2A subunits and reported alterations in AML.
Family Gene Locus Protein Alterations reported in AML
A PPP2R1A 19q13.41 PR65α/Aα Downregulation (32)
Oncogenic c-KIT mutations decrease protein levels (29)
PPP2R1B 11q23.1 PR65β/Aβ Downregulation. No good correlation between mRNA and protein (30)
Downregulation (33). Data collected as part of the Cancer Genome Atlas (TCGA)
C PPP2CA 5q31.1 PP2Acα/Cα Downregulation in TP53 mutant AML cases (33). Data collected as part of the Cancer Genome Atlas (TCGA)
PPP2CB 8p12 PP2Acβ/Cβ
B PPP2R2A 8p21.2 PR55α/B55α Oncogenic c-KIT mutations decrease protein levels (29)
Downregulation at protein level (16, 19)
Downregulation (32)
PPP2R2B 5q32 PR55β/B55β High expression (33). Data collected as part of the Cancer Genome Atlas (TCGA)
Somatic mutation (one AML case) [Data collected as part of the Cancer Genome Atlas (TCGA)]
PPP2R2C 4p16.1 PR55γ/B55γ Downregulation (33). Data collected as part of the Cancer Genome Atlas (TCGA)
PPP2R2D 10q26.3 PR55δ/B55δ
B′ PPP2R5A 1q32.3 PR61α/B56α Oncogenic c-KIT mutations decrease protein levels (29)
PPP2R5B 11q13.1 PR61β/B56β Downregulation. Good correlation between mRNA and protein (30)
High expression (33). Data collected as part of the Cancer Genome Atlas (TCGA)
PPP2R5C 14q32.31 PR61γ/B56γ Downregulation (30)
Oncogenic c-KIT mutations decrease protein levels (29)
PPP2R5D 6p21.1 PR61δ/B56δ Oncogenic c-KIT mutations decrease protein levels (29)
PPP2R5E 14q32.2 PR61ϵ/B56ϵ Downregulation. Good correlation between mRNA and protein (23)
B′′ PPP2R3A 3q22.2 PR72/PR130
PPP2R3B Yp11.32; Xp22.33 PR70/PR48 Downregulation (33). Data collected as part of the Cancer Genome Atlas (TCGA)
PPP2R3C 14q13.2 G5PR
B′′′ STRN 2p22.2 Striatin
STRN3 14q13-q12 Striatin3
STRN4 19q13.2 Striatin4
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specificity (25). Four unrelated families of regulatory PP2A-B 
subunits (B/PR55/B55, B′/PR61/B56, B′′/PR72, and B′′′/the 
striatins, STRN) have been identified, including at least 23 
different alternative transcripts and spliced forms, which deter-
mine the substrate specificity and the intracellular location of 
the PP2A complex (Figure 1; Table 1) (12, 26, 27). The actual 
challenge is not only to explore the potential therapeutic value 
of PP2A activators (28–30), but also to identify the particular 
PP2A complexes affected in each disease, in order to develop 
more efficient therapeutic strategies (31).
The precise mechanism of assembly of active PP2A holoen-
zyme is still incompletely understood [reviewed in Ref. (34)]. 
The activity of PP2A can be regulated by post-translational 
modifications. Methylation and phosphorylation of residues 
from PP2A-C subunits modulate the formation of the complex. 
For instance, methylation of leucine 309 (L309) in the catalytic 
PP2A-C subunit, by the leucine carboxyl methyltransferase 1 
(LCMT1), is indispensable for binding the PR55/B55 subunit, 
although it is not an essential requisite for other B families 
(34–36). Phosphorylation of tyrosine 307 (Y307) dramatically 
impairs PP2A phosphatase activity by inhibiting the interaction 
of PP2A-C with the PR55/B55 and PR61/B56αβγϵ subunits; 
whereas threonine 304 (T304) phosphorylation prevents the 
assembly of PR55/B55 to the core enzyme (34). Interestingly, 
increased phosphorylation of Y307 of PP2A-C is a common event 
in both cell lines and AML patient samples (30). Additionally, 
post-translational modification of B subunits can affect the sub-
cellular localization of PP2A, influencing which proteins are 
targeted (9).
We and others have reported that PP2A inhibition is a recur-
rent event in AML, and that restoration of PP2A phosphatase 
activity by treatment with PP2A-activating drugs (PADs) has 
antileukemic effects in both c-KIT wild-type (c-KIT−) and c-KIT 
mutated (c-KIT+) AML cells, inducing cell growth arrest and 
caspase-dependent apoptosis (12, 13, 29, 30, 33, 37). Furthermore, 
we have shown that PADs can be used alone or in association 
with either kinase inhibitors or traditional chemotherapy in 
AML, suggesting that PP2A rescue could represent an innovative 
therapeutic target in this disease (29, 30, 37–41).
MeCHANiSMS OF PP2A iNACTivATiON  
iN AML
Transformed cells display a wide variety of mechanisms to 
inactivate PP2A. Several somatic mutations in PP2A subunits 
have been described in different types of tumors, such as mela-
noma, lung, colon, and breast cancers (31, 42–47). Mutations of 
structural PP2A-Aα and/or PP2A-Aβ subunits cause a defective 
binding of B and C subunits, inhibiting PP2A activity and con-
tributing to cell transformation (44, 45). However, this seems to 
be an uncommon mechanism in AML. Our analysis of data from 
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the Cancer Genome Atlas Research Network (https://tcga-data.
nci.nih.gov/tcga), which analyzed the genomes of 200 patients 
with AML (50 with the use of whole-genome sequencing and 150 
with the use of whole-exome sequencing), show that only one 
case has somatic mutations in PPP2R2B, the gene encoding the 
PP2A subunit PR55β (48).
We and other groups have shown that deregulation of some 
PP2A subunits, deregulated expression of the endogenous PP2A 
inhibitors SET or cancerous inhibitor of protein phosphatase 
2A (CIP2A), or overexpression of SETBP1, contribute to PP2A 
inhibition in AML (28, 30, 40, 49, 50).
Deregulation of PP2A Subunits
Alterations of the PP2A subunits have been found in AML with 
different genetic backgrounds, contributing to the malignant 
process (Table 1). Downregulation of the Aβ subunit is a com-
mon event in AML (30). Most cellular PP2A holoenzymes con-
tain the Aα isoform of the scaffold subunit, but a small fraction 
(10%) contain a second isoform termed Aβ. As indicated above, 
mutations that disrupt the ability of Aβ to form holoenzymes 
in  vitro were identified in several types of cancer, but Sablina 
et al. provide the first hard evidence that loss of functional Aβ 
due to these cancer-associated mutations contributes to trans-
formation (8, 51). Suppression of PP2A Aβ permits immortal-
ized human cells to achieve a tumorigenic state through the 
deregulation of RaIA GTPase activity. Cancer-associated Aβ 
mutants fail to reverse this tumorigenic phenotype, indicating 
that these mutants function as null alleles (51). In addition, both 
Aα mutants and Aα downregulation lead to a functional haplo-
insufficiency that seems to induce human cell transformation by 
activating the AKT/PI3K signaling pathway (51, 52). However, 
it is likely that different sets of genetic aberrations during 
tumor formation require the loss of different PP2A holoenzyme 
complexes for the tumor progression, and this would involve 
the regulatory subunits, which are playing a key role directing 
PP2A to dephosphorylate and regulate key tumor suppressors 
or oncogenes (26).
Altered expression of the scaffold as well as the regulatory 
subunits has been reported in AML patients with c-KIT muta-
tions, which is associated with poor outcome in AML (Table 1) 
(32, 53). c-KIT is a type 3 receptor tyrosine kinase, the activation 
of which induces proliferation, differentiation, and survival. 
Oncogenic c-KIT mutations reduce PP2A activity by decreas-
ing protein levels of PR65α, PR55α, PR61α, PR61δ, and PR61γ 
(Table  1) (29). c-KIT-mediated growth and survival may be 
prevented by overexpressing PP2A-Aα in myeloid c-KIT+ cells, 
suggesting that restoration of PP2A activity in c-KIT+ AML 
patients may represent a good therapeutic strategy to overcome 
drug resistance (29).
The PP2A-PR55/B55 family consists of four different iso-
forms (α, β, γ, and δ) associated with several core-signaling 
pathways, including ARF/MDM2/p53, PI3K/AKT, Raf/MEK/
ERK, TGFBR1/TGF-β, and Wnt/β-catenin (54), and the regula-
tion of the cell cycle and mitosis (55, 56). In AML cells, PP2A-
PR55α dephosphorylates AKT on threonine 308 (T308) (15, 
16). Interestingly, increased phosphorylation of AKT correlates 
with poor outcome in AML (57). Ruvolo et  al. quantified the 
expression of several transcripts in 30 newly diagnosed patients 
with AML, and found that the expression of PPP2CA, PPP2CB 
(catalytic C subunits), and PPP2R2A (regulatory PR55α subunit) 
was elevated in blast cells. However, when they looked at protein 
expression, the levels of PR55α were low in the blast cells from the 
AML patients, suggesting different rates of translation, degrada-
tion, cleavage, or post-translational inactivation (Table 1) (16). 
As expected, they saw a link between expression of PR55α and 
AKT dephosphorylation. This suggests that strategies to promote 
PR55α inactivation of AKT may be useful for the therapy of AML 
(16). Apart from its function regulating cell survival, PR55α has 
been discovered as a modulator of the expression of microRNA 
relevant for AML, such as miR-142-3p and miR-142-5p. These 
miRs are found to be mutated in 2% of AML patients, although 
the mechanisms and the implications are still unknown (17, 
19). In addition, a recent study demonstrated that PR55α is also 
implicated in DNA damage response in AML. Cheng et al. found 
that the double-stranded RNA-activated protein kinase PKR 
activates PP2A by promoting the nuclear localization of PR55α/
B55α. Activated PP2A in turn antagonizes autophosphorylation 
and activation of ATM and its association with downstream 
targets, preventing DNA damage response and contributing to 
transformed phenotype (18). Significantly, PKR is involved in 
AML progression (58, 59), and high PKR expression is associated 
with poor overall survival and shortened remission duration for 
AML patients (18).
Several members of the PR61/B56 family of regulatory PP2A 
subunits appear to have a main role in directing PP2A potential 
tumor-suppressive activity (21, 60–63). The PP2A-PR61/B56 
regulatory family has five different isoforms (α, β, γ, δ, and ϵ) 
(49), which can bind directly to the core enzyme and be regulated 
by phosphorylation from kinases (20, 64). In acute lymphoblastic 
leukemia cells, it has been described that PKR promotes the 
mitochondrial localization of PP2A–PR61α, leading to BCL2 
dephosphorylation and inactivation and, therefore, contribut-
ing to apoptosis (20). Downregulation of PP2A–PR61β and 
PP2A–PR61γ seems to be a common event in AML cases, lead-
ing to the inactivation of PP2A, and consequently contributing 
to malignant cell proliferation (Table 1) (30). PP2A–PR61β has 
been reported as a tumor suppressor that negatively regulates 
PIM1 protein kinase, enhancing the ability of c-MYC to induce 
lymphomas (21). PP2A–PR61γ plays a crucial role in cell pro-
liferation (65), in part due to dephosphorylation of p53 (66). In 
accordance with this, it has been described that suppression of 
PR61γ expression contributes to the experimental transforma-
tion of human cells (31, 60). The function of PP2A–PR61γ in G2 
is crucial to sustain normal G0/G1 control, and this G2 PP2A 
function involves modulation of endogenous RAS signaling (22). 
Therefore, loss of PR61β/B56β and PR61γ/B56γ could be playing 
a role in AML development, contributing to deregulate the cor-
rect PP2A function.
PR61ϵ/B56ϵ is recurrently downregulated at mRNA and 
protein level in AML patients (Table 1), contributing to cell 
proliferation (23). This regulatory subunit is involved in 
multiple signaling pathways and plays critical roles during 
early development (67–69). Moreover, PR61ϵ is an essential 
regulator of apoptosis (70), and acts as a negative regulator 
FiGURe 2 | PP2A inactivation by SeT in AML. (A) PI3K can phosphorylate SET at serine 9 (S9), located in the nuclear localization signal. This phosphorylation 
translocates SET to the cytosol and impairs its return to the nucleus, increasing its ability to bind to the catalytic subunit of PP2A (PP2A-C), and inactivating PP2A 
(92, 93). Treatment with FTY720 disrupts SET–PP2A interaction, allowing PP2A activation (39). (B) SETBP1 binds directly to SET, stabilizing full-length SET and 
protecting it from protease cleavage. The complex SETBP1–SET binds PP2A through SET, inhibiting PP2A activity (50).
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of MAP4K3, mediating its ability to signal to mTORC1 (71). 
In  AML cells, PR61ϵ impairs cell proliferation, induces 
caspase-dependent apoptosis, affects the activation status of 
AKT, and reduces the colony-forming ability of the leukemic 
cells. Moreover, there is a good correlation between PR61ϵ 
downregulation and p53 levels, suggesting that the molecular 
effects of this B subunit in AML could occur, at least in part, 
via p53 (23). These results indicate that PR61ϵ downregula-
tion has relevance in AML, and could allow distinguishing a 
subgroup of patients who could benefit from receiving future 
treatments with PP2A activators.
Aberrations of the other two families of regulatory PP2A-B 
subunits have been involved in several solid tumors (31, 72–75) 
but not in AML. Therefore, further studies are necessary to 
clarify the importance of these PP2A subunits in hematological 
malignancies.
SeT/i2PP2A
The SET protein, also named I2PP2A (Inhibitor 2 of PP2A), TAF-
1β or PHAP1, is a potent endogenous inhibitor of PP2A with an 
important role in myeloid leukemias (76). SET was first identified 
as an oncogene fused with the nucleoporin NUP214 (CAN) in 
acute undifferentiated leukemia (77), and soon after, it was 
described as a PP2A inhibitor (78). This protein is located mostly 
in the nucleus, and it is implicated in many cell processes, such as 
DNA replication, chromatin remodeling, gene transcription (79, 
80), DNA repair (81), differentiation (82), migration (83), and 
cell-cycle regulation (84).
Protein phosphatase 2A is functionally inhibited as a 
consequence of the overexpression and/or post-translational 
modifications (e.g., phosphorylation) of SET, which results in an 
overall inhibition of PP2A phosphatase activity in both leukemic 
progenitors and stem cells (Figure 2) (13, 28, 29, 38, 85, 86). SET 
is upregulated in both hematological and solid tumors, including 
colorectal cancer (87) and breast cancer (88), and in most cases 
its effects as an oncogene are due to the concomitant inactivation 
of PP2A (87–90). The role of SET has been studied in depth in 
chronic myeloid leukemia (CML). SET is overexpressed in CML 
through BCR-ABL1, the constitutively active oncogenic tyrosine 
kinase that is essential for CML emergence, maintenance, and 
progression (85). Expression of BCR-ABL1 allows recruitment 
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and activation of JAK2, which in turn, enhances β-catenin activ-
ity and induces SET-mediated inactivation of PP2A (91).
We quantified the expression of SET in a series of patients with 
AML at diagnosis, observing that SET overexpression is a recur-
rent molecular event (60/214, 28%) associated with short overall 
survival in AML. Interestingly, overexpression of this oncogene 
also had prognostic impact in patients with normal karyotype, 
defining a subgroup of patients with a worse outcome. Although 
multivariate analysis confirmed SET overexpression as an inde-
pendent prognostic marker in our series, it was associated with 
other adverse prognostic markers, such as monosomy 7, SETBP1 
overexpression, and EVI1 overexpression. This observation sug-
gests that SET deregulation could cooperate with other additional 
aberrations in the leukemogenesis program. Analysis by western 
blot confirmed high SET expression at protein level in both AML 
cell lines and patient samples. In addition, we observed that 
SET promotes cell viability by inhibiting the effect of PP2A in 
AML cells, contributing to malignancy progression (38). We also 
confirmed in AML cells that SET forms an inhibitory complex 
with PP2A-C, and that the whole structure of SET (amino-
terminus and carboxy-terminus) is involved in the binding (39). 
Furthermore, the antileukemic effects of FTY720 and OP449, two 
recently discovered PADs, depend on the interaction/sequestra-
tion of SET, pointing out the importance of this oncogene in 
AML (37, 39). Nevertheless, despite the importance of SET 
overexpression and its prognostic impact in both hematological 
and solid tumors, little is known about the mechanisms involved 
in its transcriptional regulation. In addition, it has been reported 
that post-translational modification of SET can modulate SET 
affinity to PP2A. Phosphorylation at serine 9 (S9) in the nuclear 
localization signal, by either CKII (92) or PI3Kγ (93), impairs its 
returning to the nucleus, increasing its ability to inactivate PP2A 
(Figure 2A); whereas S171 phosphorylation by protein kinase D2 
(PKD2) decreases its affinity for PP2A, lowering the inhibitory 
activity (94).
Our group found another mechanism that impairs PP2A 
activity via SET in AML: the overexpression of SETBP1 (SET 
binding protein 1) (50). SETBP1 upregulation leads to binding 
and stabilization of 39 kDa full-length SET, protecting from pro-
tease cleavage. The complex SETBP1–SET binds PP2A through 
SET, provoking PP2A activity inhibition and promoting cell 
proliferation. Interestingly, 27% of AML patients have SETBP1 
overexpression, and shorter overall survival is predicted in older 
AML patients with this aberration (50) (Figure 2B). Later studies 
in other myeloid neoplasms have confirmed the important role of 
the SETBP1 oncogene in leukemogenesis.
Interestingly, SET is also implicated in natural killer (NK) cell 
cytotoxicity. After cytokine stimulation (Interleukin-12, -18, and 
-15), SET upregulation in human NK impairs IFN-γ production 
through PP2A inactivation, limiting the anti-tumor and/or anti-
inflammatory effect of NK (95). Trotta et al. described a model 
where SET–PP2A regulates granzyme B expression at mRNA 
and protein levels, and therefore, determines NK cytotoxicity. 
They observed that SET knockdown inhibited the induction of 
granzyme B expression, normally induced by stimulation of NK 
cells with IL-2 or IL-15, limiting NK cytotoxicity (96). Other 
reported functions include inhibiting the DNase activity of the 
tumor-suppressor NM23-H1, increasing AP-1 activity, or activat-
ing MAPK signaling (97, 98). These data suggest the role of SET 
not only as a PP2A inhibitor but also contributing with other 
signaling pathways to promote tumor growth.
Cancerous inhibitor of Protein 
Phosphatase 2A
Another PP2A endogenous inhibitor is CIP2A (cancerous inhibi-
tor of PP2A) (99). CIP2A controls oncogenic cellular signals by 
inhibiting PP2A activity toward the oncogenic transcription 
factor c-MYC (8, 100, 101), which plays an important role in 
AML (102). CIP2A acts by impairing PP2A activity leading to 
the stabilization of c-MYC (99).
Cancerous inhibitor of protein phosphatase 2A is expressed 
in very few normal tissues but it is overexpressed in most human 
cancer types, where it is often associated with a clinically aggres-
sive behavior (100, 101, 103–106). However, only a few studies 
have focused on AML. Wang et al., using conventional RT-PCR, 
found that 77.4% of AML cases expressed CIP2A (55 of 84), and 
confirmed their results at protein level; however, they provided 
no quantitative data (107). Recently, our group investigated its 
prevalence using quantitative real-time RT-PCR in a series of 203 
normal karyotype AML patients (NK-AML) at diagnosis, and 
reported that high CIP2A expression is a is a recurrent event in 
this AML subgroup (51/203, 25%), with a poor prognostic impact 
in the overall survival of NK-AML cases (40). Our results indicate 
that CIP2A behaves as an oncoprotein in AML. CIP2A depletion 
downregulates c-MYC, leading to a reduction of cell proliferation, 
supporting the positive relationship between CIP2A and this 
oncogenic transcription factor in AML. Nevertheless, further 
studies are needed to elucidate the role of CIP2A in AML.
Cancerous inhibitor of protein phosphatase 2A has been 
extensively studied in CML. High levels of CIP2A at diagnosis are 
significantly associated with risk of progressing to blast crisis; there-
fore, the CIP2A protein level has been proposed as a prospective 
biomarker of disease progression in imatinib-treated CML patients 
(108). Moreover, high CIP2A levels are associated with high c-MYC 
and high BCR-ABL1 tyrosine kinase activity (108). In addition, 
second-generation tyrosine kinase inhibitors (TKI) disrupt the 
CIP2A/c-MYC/E2F1 positive feedback loop, leading to lower 
disease progression risk. These data support that CIP2A inhibits 
PP2Ac, stabilizing E2F1, and creating a CIP2A/c-MYC/E2F1 posi-
tive feedback loop, which imatinib cannot overcome (109).
PP2A-ACTivATiNG DRUGS
The increased number of studies showing that PP2A is frequently 
inactivated in cancer and has raised interest in developing new 
drugs that could act as PP2A activators (12, 110). The most widely 
studied drugs are FTY720 and OP449.
FTY720 is an oral sphingosine analog derived from myriocin, 
a metabolite isolated from fungus Isaria Sinclairii that has been 
approved for the treatment of patients with relapsing multiple 
sclerosis (111). After phosphorylation by sphingosine kinase 2 
(SPHK2), FTY720 binds to one of the sphingosine-1-phosphate 
receptor (S1P1, S1P3, S1P4, or S1P5). Phosphorylated FTY720 does 
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not impair T-lymphocyte or B-lymphocyte activation, but does 
interfere with immune cell trafficking between lymphoid organs 
and peripheral blood (112).
FTY720 is also a potent inhibitor of tumor growth and 
angiogenesis, pointing to the use of this drug in the treatment 
of both solid and hematological tumors. The anticancer activity 
of FTY720 depends on its ability, at least in leukemias, to act as a 
potent PP2A activator [reviewed in Ref. (86)]. FTY720-induced 
PP2A activity induces apoptosis by interfering with BCL2; and 
suppresses mitogenic and survival signals by inhibiting the ERK 
and PI3K/AKT pathways (13, 28, 32, 39, 41, 113–115).
The effects induced by FTY720 are well characterized in both 
Ph positive and negative leukemias. Several reports highlight the 
efficacy of FTY720 in vitro and in vivo models of AML, reporting 
restored PP2A activity, decreased clonogenicity, and suppression 
of disease (12, 38–41). In CML and Ph-positive B-ALL progeni-
tors, FTY720 promotes BCR-ABL1 inactivation and degradation. 
This leads to inhibition of survival factors (such as JAK2, AKT, 
and ERK1/2), which result in apoptosis of CD34+ progenitors in 
patients with TKI sensitive and TKI-resistant CML (12, 28, 85). 
These findings are promising in CML and in other myeloprolif-
erative neoplasms, suggesting the possibility that patients could 
be brought into remission by TKIs and then treated with FTY720 
or its derivatives (12).
Mechanistically, as indicated above, FTY720 prevents 
SET/PP2A-C binding through its interaction with SET in 
a C-terminal hydrophobic pocket that contains a globular 
amphipathic domain (116). Our group confirmed these results 
in AML (39). FTY720, which binds SET within the last 100 
amino acids of the C-terminal fragment (39, 117), produces 
a destabilization of the SET/PP2A-C complex, leading to the 
reactivation of PP2A function and a reduction of AML cell 
viability (39). Interestingly, FTY720 not only disrupts com-
plex formation between SET and PP2A-C but it also induces 
increased translocation of SET to the nucleus (39), possibly by 
reducing the phosphorylation of SET S9 without affecting the 
protein levels (86) (Figure 2A). Moreover, apart from induc-
ing apoptosis of AML cells by reactivation of PP2A activity, 
FTY720 treatment could perturb the sphingolipid metabolism 
pathway. This disruption leads to the accumulation of ceramide, 
a pro-apoptotic second messenger, mostly in the mitochondria 
membrane, contributing to the death of AML cells (115). 
In  addition, in a recent study in in  vitro and in  vivo models 
of AML, we found that FTY720 lipid nanoparticles were more 
efficient at inducing cell growth arrest and apoptosis than 
FTY720 in solution in AML cells. Interestingly, the use of lipid 
nanoparticles containing FTY720 significantly increased oral 
bioavailability of the free drug. These results provide the first 
evidence for the potential use of FTY720 lipid nanoparticles as 
an oral therapeutic agent in AML (41).
Since the anticancer activity of FTY720 does not require 
SPHK2 phosphorylation or S1PR1 interaction, and FTY720-P 
seems to have pro-proliferative properties [reviewed in Ref. (12)], 
it has been proposed that FTY720 analogs that are not targets for 
phosphorylation by SPHK2, as [S]-FTY720-OMe, [S]-FTY720-
regioisomer, and OSU-2S, may have less toxicity and be more 
useful as anticancer drugs. Of note, these FTY720 derivatives do 
not induce lymphopenia, undergo phosphorylation, or interact 
with the S1PR1 receptor [(13), reviewed in Ref. (12)].
Other novel molecules have been tested to activate PP2A 
in AML, such as the small peptide OP449 (118). OP449 was 
reported as a novel, physiologically stable, cell-penetrating pep-
tide, which binds specifically to SET and antagonizes the inhibi-
tion of PP2A. Furthermore, OP449 treatment suppresses growth, 
enhances apoptosis, and impairs clonogenicity of CML and AML 
cell lines and primary patient cells, leading to the activation of 
the PP2A function. It has been reported that the SET binding 
peptides COG112 and OP449 reactivate PP2A upon interaction 
with SET, preventing SET–PP2Ac interaction and, therefore, the 
inhibition of PP2A activity (90, 118). Furthermore, the combina-
tion of OP449 with specific TKI or chemotherapy in treatment 
of CML and AML cell lines and primary patient samples have 
synergistic effects (37). These findings open new possibilities to 
establish innovative strategies for combined therapy that targets 
PP2A and tyrosine kinase signaling pathways in order to improve 
therapeutic options in AML patients.
CONCLUSiON
Despite progressive advances in our understanding of the 
molecular biology of AML, the general therapeutic strategy in 
patients with this leukemia has not changed substantially, and 
the outcome for most patients is poor. New compounds target-
ing a variety of cellular processes have been developed for the 
treatment of AML, although few have been translated into clinical 
practice. Nevertheless, it is unlikely that any of these compounds, 
when used as single agents, will cure the disease, which sug-
gests the need for combinatorial therapy (7). Furthermore, the 
results of the Cancer Genome Atlas Research Network confirm 
the molecular heterogeneity of this disease, and show that genes 
that are significantly mutated in AML are organized into several 
functional categories, suggesting the importance of developing 
treatments directed at target pathways (48). In this regard, the 
tumor-suppressor PP2A has emerged as a promising therapeutic 
target in AML, since it is a negative regulator of several survival 
and proliferation pathways that are frequently activated in AML 
as a result of aberrant activation of oncogenic kinases.
Protein phosphatase 2A inactivation is a recurrent event in 
AML, and restoration of its activity by PADs has antileukemic 
effects in both KIT-positive and KIT-negative AML cells. 
Preclinical studies show that pharmacological restoration of 
PP2A tumor-suppressor activity by PADs (e.g., FTY720, FTY720 
analogs, or OP499) effectively antagonizes leukemogenesis, and 
that these drugs have synergistic cytotoxic effects with both con-
ventional chemotherapy and TKIs, opening new possibilities for 
precision medicine, or personalized treatment, in AML patients 
(30, 37, 41). Interestingly, the anticancer activity of several PADs 
depends on interaction/sequestration of its endogenous inhibitor 
SET, an oncogene overexpressed in 28% of AML patients (38).
These results indicate that the combination of kinase inhibitors 
and PADs may be a valid therapeutic option for AML, especially 
for treating leukemias characterized by SET-dependent inac-
tivation of PP2A. Therefore, PADs might be clinically relevant 
anticancer drugs that could be introduced into therapeutic 
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protocols for patients with hematopoietic and non-hematopoietic 
malignancies characterized by functional loss of the PP2A tumor 
suppressor (13, 37).
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